Raymond James Reiterates Outperform Rating on BridgeBio Oncology Therapeutics, In (BBOT)

September 15, 2026 3:17 AM EDT Send to a Friend
Raymond James analyst Sean McCutcheon reiterated an Outperform rating and {REMOVEPT} price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT)The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login